179 related articles for article (PubMed ID: 31251613)
1. Mechanism of Inactivation of Ornithine Aminotransferase by (1
Moschitto MJ; Doubleday PF; Catlin DS; Kelleher NL; Liu D; Silverman RB
J Am Chem Soc; 2019 Jul; 141(27):10711-10721. PubMed ID: 31251613
[TBL] [Abstract][Full Text] [Related]
2. Structural and Kinetic Analyses Reveal the Dual Inhibition Modes of Ornithine Aminotransferase by (1
Butrin A; Beaupre BA; Kadamandla N; Zhao P; Shen S; Silverman RB; Moran GR; Liu D
ACS Chem Biol; 2021 Jan; 16(1):67-75. PubMed ID: 33316155
[TBL] [Abstract][Full Text] [Related]
3. Structural and Mechanistic Basis for the Inactivation of Human Ornithine Aminotransferase by (3
Shen S; Butrin A; Beaupre BA; Ferreira GM; Doubleday PF; Grass DH; Zhu W; Kelleher NL; Moran GR; Liu D; Silverman RB
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770800
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Mechanistic Studies of (
Devitt AN; Vargas AL; Zhu W; Des Soye BJ; Butun FA; Alt T; Kaley N; Ferreira GM; Moran GR; Kelleher NL; Liu D; Silverman RB
ACS Chem Biol; 2024 May; 19(5):1066-1081. PubMed ID: 38630468
[TBL] [Abstract][Full Text] [Related]
5. Remarkable and Unexpected Mechanism for (
Zhu W; Doubleday PF; Butrin A; Weerawarna PM; Melani RD; Catlin DS; Dwight TA; Liu D; Kelleher NL; Silverman RB
J Am Chem Soc; 2021 Jun; 143(21):8193-8207. PubMed ID: 34014654
[TBL] [Abstract][Full Text] [Related]
6. A Remarkable Difference That One Fluorine Atom Confers on the Mechanisms of Inactivation of Human Ornithine Aminotransferase by Two Cyclohexene Analogues of γ-Aminobutyric Acid.
Zhu W; Doubleday PF; Catlin DS; Weerawarna PM; Butrin A; Shen S; Wawrzak Z; Kelleher NL; Liu D; Silverman RB
J Am Chem Soc; 2020 Mar; 142(10):4892-4903. PubMed ID: 32114761
[TBL] [Abstract][Full Text] [Related]
7. Selective Targeting by a Mechanism-Based Inactivator against Pyridoxal 5'-Phosphate-Dependent Enzymes: Mechanisms of Inactivation and Alternative Turnover.
Mascarenhas R; Le HV; Clevenger KD; Lehrer HJ; Ringe D; Kelleher NL; Silverman RB; Liu D
Biochemistry; 2017 Sep; 56(37):4951-4961. PubMed ID: 28816437
[TBL] [Abstract][Full Text] [Related]
8. Rational Design, Synthesis, and Mechanism of (3
Zhu W; Butrin A; Melani RD; Doubleday PF; Ferreira GM; Tavares MT; Habeeb Mohammad TS; Beaupre BA; Kelleher NL; Moran GR; Liu D; Silverman RB
J Am Chem Soc; 2022 Mar; 144(12):5629-5642. PubMed ID: 35293728
[TBL] [Abstract][Full Text] [Related]
9. Turnover and Inactivation Mechanisms for (
Shen S; Butrin A; Doubleday PF; Melani RD; Beaupre BA; Tavares MT; Ferreira GM; Kelleher NL; Moran GR; Liu D; Silverman RB
J Am Chem Soc; 2021 Jun; 143(23):8689-8703. PubMed ID: 34097381
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase.
Zigmond E; Ben Ya'acov A; Lee H; Lichtenstein Y; Shalev Z; Smith Y; Zolotarov L; Ziv E; Kalman R; Le HV; Lu H; Silverman RB; Ilan Y
ACS Med Chem Lett; 2015 Aug; 6(8):840-4. PubMed ID: 26288681
[TBL] [Abstract][Full Text] [Related]
11. Determination of the pH dependence, substrate specificity, and turnovers of alternative substrates for human ornithine aminotransferase.
Butrin A; Butrin A; Wawrzak Z; Moran GR; Liu D
J Biol Chem; 2022 Jun; 298(6):101969. PubMed ID: 35460691
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic crystallography. Mechanism of inactivation of gamma-aminobutyric acid aminotransferase by (1R,3S,4S)-3-amino-4-fluorocyclopentane-1-carboxylic acid as elucidated by crystallography.
Storici P; Qiu J; Schirmer T; Silverman RB
Biochemistry; 2004 Nov; 43(44):14057-63. PubMed ID: 15518554
[TBL] [Abstract][Full Text] [Related]
13. Ornithine aminotransferase versus GABA aminotransferase: implications for the design of new anticancer drugs.
Lee H; Juncosa JI; Silverman RB
Med Res Rev; 2015 Mar; 35(2):286-305. PubMed ID: 25145640
[TBL] [Abstract][Full Text] [Related]
14. Structural modifications of (1S,3S)-3-amino-4-difluoromethylenecyclopentanecarboxylic acid, a potent irreversible inhibitor of GABA aminotransferase.
Yuan H; Silverman RB
Bioorg Med Chem Lett; 2007 Mar; 17(6):1651-4. PubMed ID: 17267220
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of human ornithine aminotransferase complexed with the highly specific and potent inhibitor 5-fluoromethylornithine.
Storici P; Capitani G; Müller R; Schirmer T; Jansonius JN
J Mol Biol; 1999 Jan; 285(1):297-309. PubMed ID: 9878407
[TBL] [Abstract][Full Text] [Related]
16. Human ornithine aminotransferase complexed with L-canaline and gabaculine: structural basis for substrate recognition.
Shah SA; Shen BW; Brünger AT
Structure; 1997 Aug; 5(8):1067-75. PubMed ID: 9309222
[TBL] [Abstract][Full Text] [Related]
17. Prevention of ornithine cytotoxicity by proline in human retinal pigment epithelial cells.
Ueda M; Masu Y; Ando A; Maeda H; Del Monte MA; Uyama M; Ito S
Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):820-7. PubMed ID: 9538890
[TBL] [Abstract][Full Text] [Related]
18. Ornithine aminotransferase, a potential target for the treatment of hyperammonemias.
Seiler N
Curr Drug Targets; 2000 Sep; 1(2):119-53. PubMed ID: 11465067
[TBL] [Abstract][Full Text] [Related]
19. Studies on the turnover rates of ornithine aminotransferase in Morris hepatoma 44 and host liver.
Kobayashi K; Morris HP; Katunuma N
J Biochem; 1976 Nov; 80(5):1085-9. PubMed ID: 187580
[TBL] [Abstract][Full Text] [Related]
20. DL-canaline and 5-fluoromethylornithine. Comparison of two inactivators of ornithine aminotransferase.
Bolkenius FN; Knödgen B; Seiler N
Biochem J; 1990 Jun; 268(2):409-14. PubMed ID: 2363680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
